I.g

Pulmonary fibrosis

(Fr: fibrose pulmonaire). The background incidence of idiopathic pulmonary fibrosis (IPF) has to be taken into account for causality assessment. Imaging at PMID 23672718. The diagnosis of interstitial pulmonary fibrosis is raised in the presence of linear pulmonary opacities and architectural distortion on imaging incl. HRCT, restrictive lung dysfunction, low KCO, and hypoxemia obviating the need for a lung biopsy. Presentation can be chronic, subacute or rapidly progressive. Generally, the condition develops insidiously with dyspnea and bibasilar or diffuse reticular or streaky opacities. Honeycombing can develop with time in longterm survivors. DI-fibrosis may follow a classic episode of chemotherapy- or amiodarone-induced pulmonary toxicity. Separation of DI-fibrosis from idiopathic or CTD (viz. RA or scleroderma)-related fibrosis can be arduous (PMID 23791462). Patients may exacerbate and progress to ARDS. DI-fibrosis may develop late after completion of therapy with chemo agents, irradiation or amiodarone with no evidence of toxicity during treatment or in the meantime. DI-fibrosis rarely occurs as a complication of patterns Ia, b or c. Oxygen and irradiation can trigger the onset of or exacerbate DI-fibrosis. When DI-fibrosis develops during treatment with the offending agent, drug withdrawal may translate into some improvement. Costicosteroid therapy is indicated, but the results are unpredictable
Last update : 17/04/2017
 

Causative drugs

81

Adalimumab

I.a I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD), acute, severe (see also under ARDS)
I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD)
I.c I - Interstitial/parenchymal lung disease
I.c - Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)
I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia (A pattern consistent with)
I.g I - Interstitial/parenchymal lung disease
I.g - Pulmonary fibrosis
I.m I - Interstitial/parenchymal lung disease
I.m - ILD with a granulomatous component
I.w I - Interstitial/parenchymal lung disease
I.w - Rapidly progressive ILD or pulmonary fibrosis (Hamman-Rich syndrome)
II.b II - Pulmonary edema - ARDS - Acute respiratory failure
II.b - ARDS
IV.a IV - Airway involvement
IV.a - Bronchospasm - Asthma
V.d V - Pleural and/or pericardial involvement
V.d - Pleural/pericardial effusion, ANA positive (DI lupus)
V.m V - Pleural and/or pericardial involvement
V.m - Pleuropericardial effusion (ANA unknown or negative)
IX.j IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.j - Phrenic nerve injury - Hemidiaphragmatic paralysis
X.b X - Systemic conditions, syndromes and reactions
X.b - Antiphospholipid antibodies w/wo the APL syndrome
X.j X - Systemic conditions, syndromes and reactions
X.j - Myositis/polymyositis/DPM/rhabdomyolysis/myopathy
X.k X - Systemic conditions, syndromes and reactions
X.k - Sarcoid-like, granulomatous thoracic and/or extrathoracic reaction
X.s X - Systemic conditions, syndromes and reactions
X.s - Pulmonary/systemic vasculitis/polyangiitis (ANCA-positive)
XV.e XV - Pulmonary pathology
XV.e - Path: ILD with a granulomatous component (see also Im)
XVII.b XVII - Infections & related conditions
XVII.b - Opportunistic pulmonary/systemic infection
XVII.c XVII - Infections & related conditions
XVII.c - Aspergillosis, pulmonary
XVII.e XVII - Infections & related conditions
XVII.e - Pneumocystis jiroveci pneumonia
XVII.f XVII - Infections & related conditions
XVII.f - Tuberculosis, miliary
XVII.g XVII - Infections & related conditions
XVII.g - Tuberculosis (pulmonary, extrapulmonary, reactivation or de novo)
XVII.z XVII - Infections & related conditions
XVII.z - Histoplamosis (reactivation)
XVII.aa XVII - Infections & related conditions
XVII.aa - Coccidioidomycosis
1

Amiodarone

I.a I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD), acute, severe (see also under ARDS)
I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD)
I.c I - Interstitial/parenchymal lung disease
I.c - Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)
I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia (A pattern consistent with)
I.f I - Interstitial/parenchymal lung disease
I.f - Acute fibrinous organizing pneumonia (AFOP)
I.g I - Interstitial/parenchymal lung disease
I.g - Pulmonary fibrosis
I.h I - Interstitial/parenchymal lung disease
I.h - Subclinical pulmonary opacities
I.k I - Interstitial/parenchymal lung disease
I.k - Lung nodule or nodules
I.l I - Interstitial/parenchymal lung disease
I.l - Diffuse alveolar damage (DAD) (see alsoo under IIb and XVf)
I.r I - Interstitial/parenchymal lung disease
I.r - Amiodarone pulmonary toxicity
I.s I - Interstitial/parenchymal lung disease
I.s - A mass or masses
I.u I - Interstitial/parenchymal lung disease
I.u - Relapsing or migrating pneumonitis/pneumonia (see also Id)
I.w I - Interstitial/parenchymal lung disease
I.w - Rapidly progressive ILD or pulmonary fibrosis (Hamman-Rich syndrome)
I.z I - Interstitial/parenchymal lung disease
I.z - Areas of consolidation
I.aa I - Interstitial/parenchymal lung disease
I.aa - Delayed ILD, -pneumonitis, -fibrosis
II.b II - Pulmonary edema - ARDS - Acute respiratory failure
II.b - ARDS
II.l II - Pulmonary edema - ARDS - Acute respiratory failure
II.l - Postoperative ARDS
III.a III - Pulmonary hemorrhage
III.a - Diffuse alveolar hemorrhage (DAH)
III.c III - Pulmonary hemorrhage
III.c - Hemoptysis
IV.a IV - Airway involvement
IV.a - Bronchospasm - Asthma
IV.d IV - Airway involvement
IV.d - Cough (lone)
IV.r IV - Airway involvement
IV.r - Airway pigmentation (black, bluish, petechial)
V.a V - Pleural and/or pericardial involvement
V.a - Pleural effusion
V.c V - Pleural and/or pericardial involvement
V.c - Pleural thickening/fibrosis - Fibrothorax
V.d V - Pleural and/or pericardial involvement
V.d - Pleural/pericardial effusion, ANA positive (DI lupus)
VI.a VI - Pulmonary vasculopathy
VI.a - Pulmonary embolism - Venous thromboembolism
VI.i VI - Pulmonary vasculopathy
VI.i - Acute pulmonary hypertension
VIII.a VIII - Upper, central, large airway involvement
VIII.a - Angioedema (may cause UAO & asphyxia)
IX.a IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.a - Diaphragm/inspiratory muscle weakness/paralysis (w/wo ARF)
IX.d IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.d - Ventilatory depression-Hypoventilation (may cause ARF). See also XIe
X.d X - Systemic conditions, syndromes and reactions
X.d - Lupus - Lupus syndrome (see also Vd)
X.f X - Systemic conditions, syndromes and reactions
X.f - Anaphylaxis
XI.c XI - Miscellaneous
XI.c - Pleuritic chest pain (see also under Vi)
XI.f XI - Miscellaneous
XI.f - Pseudocyanotic skin discoloration (see also XIa, XIVa, XIVb)
XII.a XII - Cardiovascular involvement / toxicity
XII.a - Left ventricular dysfunction/failure
XII.c XII - Cardiovascular involvement / toxicity
XII.c - Pericarditis, pericardial effusion, tamponade
XII.l XII - Cardiovascular involvement / toxicity
XII.l - Cardiac arrhythmias or dysrhythmias (AF, VT, VF, TdP)
XII.n XII - Cardiovascular involvement / toxicity
XII.n - Hypotension, shock, cardiovascular collapse
XII.p XII - Cardiovascular involvement / toxicity
XII.p - QT prolongation
XII.af XII - Cardiovascular involvement / toxicity
XII.af - Coronary arterial spasm
XV.a XV - Pulmonary pathology
XV.a - Path: Cellular NSIP pattern (see also Ia, Ib)
XV.b XV - Pulmonary pathology
XV.b - Path: Eosinophilic pneumonia (subacute or acute) (see also Ic)
XV.c XV - Pulmonary pathology
XV.c - Path: Organizing pneumonia (OP/BOOP) pattern (see also Id)
XV.d XV - Pulmonary pathology
XV.d - Path: Acute fibrinous organizing pneumonia (AFOP-pattern) (see also If)
XV.f XV - Pulmonary pathology
XV.f - Path: Diffuse alveolar damage (DAD-pattern) (see also IL)
XV.g XV - Pulmonary pathology
XV.g - Path: Alveolar hemorrhage (see also IIIa)
XV.h XV - Pulmonary pathology
XV.h - Path: Fibrotic NSIP pattern
XV.i XV - Pulmonary pathology
XV.i - Path: Pneumocyte atypia (reactive epithelial cells)
XV.j XV - Pulmonary pathology
XV.j - Path: Pulmonary fibrosis (UIP-pattern)
XV.k XV - Pulmonary pathology
XV.k - Path: Desquamative interstitial pneumonia (DIP-pattern)
XV.m XV - Pulmonary pathology
XV.m - Path: Lymphoid hyperplasia - LIP-pattern
XV.o XV - Pulmonary pathology
XV.o - Path: Endogenous lipoid pneumonia (phospholipidosis)
XV.r XV - Pulmonary pathology
XV.r - Path: Smudged geographic necrosis
XV.ao XV - Pulmonary pathology
XV.ao - Path: Pleuritis, pleural fibrosis
XV.bt XV - Pulmonary pathology
XV.bt - Path: Histiocytic proliferation
XVI.b XVI - Imaging
XVI.b - Imaging: Ground-glass shadowing/opacities (GGO)
XVI.i XVI - Imaging
XVI.i - Imaging: An area or areas of involvement with a recognizable anatomic distribution
XVI.n XVI - Imaging
XVI.n - Imaging: Intralobular septal thickening - Crazy paving
XVI.s XVI - Imaging
XVI.s - Imaging: An area or areas of involvement with high attenuation numbers or metallic density
XVI.aa XVI - Imaging
XVI.aa - Imaging: Nodules, mass or masses with a central area of low attenuation (see also under XVIaa)
XVI.ab XVI - Imaging
XVI.ab - Imaging: Cavitating lung nodules (see also Iq, XIs, XIIi, XVIaa and XVIIp)
XVI.az XVI - Imaging
XVI.az - Imaging: Solitary pulmonary nodule
XVI.bj XVI - Imaging
XVI.bj - Imaging: Atelectasis (a combination of increased density and volume loss. Typically lobar)
XVIII.b XVIII - Distinctive patterns - 'Eye-catchers'
XVIII.b - Eye catcher: Electron-dense area or areas of consolidation on unenhanced CT
XVIII.k XVIII - Distinctive patterns - 'Eye-catchers'
XVIII.k - Eye-catcher: An electron-dense liver on unenhanced CT
XVIII.p XVIII - Distinctive patterns - 'Eye-catchers'
XVIII.p - Eye-catcher: An electron-dense ('white') thyroid
XIX.a XIX - Cytology, biochemistry of BAL, pleural fluid or FNA
XIX.a - BAL: An excess proportion of lymphocytes
XIX.b XIX - Cytology, biochemistry of BAL, pleural fluid or FNA
XIX.b - BAL: An excess proportion of neutrophils
XIX.e XIX - Cytology, biochemistry of BAL, pleural fluid or FNA
XIX.e - BAL: Stainable iron in macrophages
XIX.f XIX - Cytology, biochemistry of BAL, pleural fluid or FNA
XIX.f - BAL: Foamy macrophages in BAL, pleural fluid, or FNA
XIX.m XIX - Cytology, biochemistry of BAL, pleural fluid or FNA
XIX.m - BAL: A normal cell differential
3

Azathioprine

I.a I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD), acute, severe (see also under ARDS)
I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD)
I.c I - Interstitial/parenchymal lung disease
I.c - Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)
I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia (A pattern consistent with)
I.g I - Interstitial/parenchymal lung disease
I.g - Pulmonary fibrosis
I.l I - Interstitial/parenchymal lung disease
I.l - Diffuse alveolar damage (DAD) (see alsoo under IIb and XVf)
I.m I - Interstitial/parenchymal lung disease
I.m - ILD with a granulomatous component
I.q I - Interstitial/parenchymal lung disease
I.q - Nodules in lung parenchyma (a.k.a. nodulosis)
I.ah I - Interstitial/parenchymal lung disease
I.ah - Acute restrictive lung dysfunction
II.b II - Pulmonary edema - ARDS - Acute respiratory failure
II.b - ARDS
III.a III - Pulmonary hemorrhage
III.a - Diffuse alveolar hemorrhage (DAH)
VIII.a VIII - Upper, central, large airway involvement
VIII.a - Angioedema (may cause UAO & asphyxia)
X.g X - Systemic conditions, syndromes and reactions
X.g - Hypersensitivity reaction (may involve skin, throat and/or airways)
X.o X - Systemic conditions, syndromes and reactions
X.o - Neutrophilic dermatosis (Pyoderma, Sweet)
XII.h XII - Cardiovascular involvement / toxicity
XII.h - Eosinophilic myocarditis
XIII.b XIII - Neoplastic conditions
XIII.b - Lymphoproliferative disease (pulmonary, endothoracic)
XV.a XV - Pulmonary pathology
XV.a - Path: Cellular NSIP pattern (see also Ia, Ib)
XV.e XV - Pulmonary pathology
XV.e - Path: ILD with a granulomatous component (see also Im)
XV.f XV - Pulmonary pathology
XV.f - Path: Diffuse alveolar damage (DAD-pattern) (see also IL)
XV.j XV - Pulmonary pathology
XV.j - Path: Pulmonary fibrosis (UIP-pattern)
XV.bq XV - Pulmonary pathology
XV.bq - Path: Lymphoproliferative disease, endothoracic
XVII.e XVII - Infections & related conditions
XVII.e - Pneumocystis jiroveci pneumonia
XVII.h XVII - Infections & related conditions
XVII.h - Nontuberculous mycobacterial infection
1

Beta-blockers

I.a I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD), acute, severe (see also under ARDS)
I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD)
I.c I - Interstitial/parenchymal lung disease
I.c - Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)
I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia (A pattern consistent with)
I.g I - Interstitial/parenchymal lung disease
I.g - Pulmonary fibrosis
I.u I - Interstitial/parenchymal lung disease
I.u - Relapsing or migrating pneumonitis/pneumonia (see also Id)
II.a II - Pulmonary edema - ARDS - Acute respiratory failure
II.a - Pulmonary edema, noncardiogenic (NCPE)
IV.a IV - Airway involvement
IV.a - Bronchospasm - Asthma
IV.f IV - Airway involvement
IV.f - Severe, catastrophic asthma attack (can be fatal)
V.a V - Pleural and/or pericardial involvement
V.a - Pleural effusion
V.c V - Pleural and/or pericardial involvement
V.c - Pleural thickening/fibrosis - Fibrothorax
V.d V - Pleural and/or pericardial involvement
V.d - Pleural/pericardial effusion, ANA positive (DI lupus)
VI.w VI - Pulmonary vasculopathy
VI.w - Worsening of preexisting PHTn
IX.d IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.d - Ventilatory depression-Hypoventilation (may cause ARF). See also XIe
IX.d IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.d - Ventilatory depression-Hypoventilation (may cause ARF). See also XIe
X.d X - Systemic conditions, syndromes and reactions
X.d - Lupus - Lupus syndrome (see also Vd)
X.y X - Systemic conditions, syndromes and reactions
X.y - Subclinical ANA positivity
XI.r XI - Miscellaneous
XI.r - Death following exposure or poisoning
XI.af XI - Miscellaneous
XI.af - Refractoriness to epineprine in case of anaphylaxis
XII.m XII - Cardiovascular involvement / toxicity
XII.m - Cardiac/cardiopulmonary arrest
1

Bleomycin

I.a I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD), acute, severe (see also under ARDS)
I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD)
I.c I - Interstitial/parenchymal lung disease
I.c - Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)
I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia (A pattern consistent with)
I.f I - Interstitial/parenchymal lung disease
I.f - Acute fibrinous organizing pneumonia (AFOP)
I.g I - Interstitial/parenchymal lung disease
I.g - Pulmonary fibrosis
I.k I - Interstitial/parenchymal lung disease
I.k - Lung nodule or nodules
I.l I - Interstitial/parenchymal lung disease
I.l - Diffuse alveolar damage (DAD) (see alsoo under IIb and XVf)
I.v I - Interstitial/parenchymal lung disease
I.v - Subclinical changes in lung function/PFT
I.w I - Interstitial/parenchymal lung disease
I.w - Rapidly progressive ILD or pulmonary fibrosis (Hamman-Rich syndrome)
II.b II - Pulmonary edema - ARDS - Acute respiratory failure
II.b - ARDS
V.f V - Pleural and/or pericardial involvement
V.f - Pneumothorax
V.p V - Pleural and/or pericardial involvement
V.p - Pleuroparenchymal fibroelastosis (PPFE)
VI.c VI - Pulmonary vasculopathy
VI.c - Pulmonary veno-occlusive disease
VI.f VI - Pulmonary vasculopathy
VI.f - The hemolytic and uremic syndrome (HUS). See also under Xaf
VII.e VII - Mediastinal involvement
VII.e - Granulomatous mediastinal lymphadenopathy
VII.h VII - Mediastinal involvement
VII.h - Pneumomediastinum
XI.b XI - Miscellaneous
XI.b - Chest pain (acute - subacute)
XI.c XI - Miscellaneous
XI.c - Pleuritic chest pain (see also under Vi)
XV.a XV - Pulmonary pathology
XV.a - Path: Cellular NSIP pattern (see also Ia, Ib)
XV.b XV - Pulmonary pathology
XV.b - Path: Eosinophilic pneumonia (subacute or acute) (see also Ic)
XV.c XV - Pulmonary pathology
XV.c - Path: Organizing pneumonia (OP/BOOP) pattern (see also Id)
XV.d XV - Pulmonary pathology
XV.d - Path: Acute fibrinous organizing pneumonia (AFOP-pattern) (see also If)
XV.f XV - Pulmonary pathology
XV.f - Path: Diffuse alveolar damage (DAD-pattern) (see also IL)
XV.h XV - Pulmonary pathology
XV.h - Path: Fibrotic NSIP pattern
XV.i XV - Pulmonary pathology
XV.i - Path: Pneumocyte atypia (reactive epithelial cells)
XV.ax XV - Pulmonary pathology
XV.ax - Path: Focal organizing pneumonia
XV.be XV - Pulmonary pathology
XV.be - Path: Interstitial pulmonary edema
XV.bf XV - Pulmonary pathology
XV.bf - Path: Pulmonary necrotizing granuloma
XVI.a XVI - Imaging
XVI.a - Imaging: Diffuse haze
XVI.b XVI - Imaging
XVI.b - Imaging: Ground-glass shadowing/opacities (GGO)
XVI.e XVI - Imaging
XVI.e - Imaging: Pulmonary opacities with a subpleural distribution
XVI.k XVI - Imaging
XVI.k - Imaging: An area or areas of consolidation
XVI.w XVI - Imaging
XVI.w - Imaging: Lung nodule or several nodules
XVI.ab XVI - Imaging
XVI.ab - Imaging: Cavitating lung nodules (see also Iq, XIs, XIIi, XVIaa and XVIIp)
XVI.af XVI - Imaging
XVI.af - Imaging: Lung cysts or bullae (see also XVI ah/bf)
XVI.bl XVI - Imaging
XVI.bl - Imaging: Avid lung uptake on PET-scan
XVIII.j XVIII - Distinctive patterns - 'Eye-catchers'
XVIII.j - Eye-catcher: Avid lung uptake on PET-scan
XIX.b XIX - Cytology, biochemistry of BAL, pleural fluid or FNA
XIX.b - BAL: An excess proportion of neutrophils
2

Chemotherapy (antineoplastic)

I.a I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD), acute, severe (see also under ARDS)
I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD)
I.c I - Interstitial/parenchymal lung disease
I.c - Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)
I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia (A pattern consistent with)
I.f I - Interstitial/parenchymal lung disease
I.f - Acute fibrinous organizing pneumonia (AFOP)
I.g I - Interstitial/parenchymal lung disease
I.g - Pulmonary fibrosis
I.h I - Interstitial/parenchymal lung disease
I.h - Subclinical pulmonary opacities
I.k I - Interstitial/parenchymal lung disease
I.k - Lung nodule or nodules
I.l I - Interstitial/parenchymal lung disease
I.l - Diffuse alveolar damage (DAD) (see alsoo under IIb and XVf)
I.m I - Interstitial/parenchymal lung disease
I.m - ILD with a granulomatous component
I.n I - Interstitial/parenchymal lung disease
I.n - Pulmonary alveolar proteinosis (PAP)
I.v I - Interstitial/parenchymal lung disease
I.v - Subclinical changes in lung function/PFT
I.w I - Interstitial/parenchymal lung disease
I.w - Rapidly progressive ILD or pulmonary fibrosis (Hamman-Rich syndrome)
I.x I - Interstitial/parenchymal lung disease
I.x - Pleuroparenchymal fibroelastosis (PPFE)
I.y I - Interstitial/parenchymal lung disease
I.y - Progression, acceleration or exacerbation of preexisting ILD/fibrosis
I.aa I - Interstitial/parenchymal lung disease
I.aa - Delayed ILD, -pneumonitis, -fibrosis
I.ad I - Interstitial/parenchymal lung disease
I.ad - Radiation recall pneumonitis
II.a II - Pulmonary edema - ARDS - Acute respiratory failure
II.a - Pulmonary edema, noncardiogenic (NCPE)
II.b II - Pulmonary edema - ARDS - Acute respiratory failure
II.b - ARDS
II.c II - Pulmonary edema - ARDS - Acute respiratory failure
II.c - ARDS and the hemolytic-uremic syndrome (HUS)
II.d II - Pulmonary edema - ARDS - Acute respiratory failure
II.d - Pulmonary edema, cardiogenic
III.a III - Pulmonary hemorrhage
III.a - Diffuse alveolar hemorrhage (DAH)
IV.a IV - Airway involvement
IV.a - Bronchospasm - Asthma
V.a V - Pleural and/or pericardial involvement
V.a - Pleural effusion
V.f V - Pleural and/or pericardial involvement
V.f - Pneumothorax
VI.b VI - Pulmonary vasculopathy
VI.b - Pulmonary arterial hypertension
VI.c VI - Pulmonary vasculopathy
VI.c - Pulmonary veno-occlusive disease
VI.f VI - Pulmonary vasculopathy
VI.f - The hemolytic and uremic syndrome (HUS). See also under Xaf
VII.a VII - Mediastinal involvement
VII.a - Lymphadenopathy (intrathoracic)
VII.h VII - Mediastinal involvement
VII.h - Pneumomediastinum
VIII.a VIII - Upper, central, large airway involvement
VIII.a - Angioedema (may cause UAO & asphyxia)
IX.f IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.f - Hiccup
IX.j IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.j - Phrenic nerve injury - Hemidiaphragmatic paralysis
IX.o IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.o - Pneumorachis
X.c X - Systemic conditions, syndromes and reactions
X.c - Capillary/vascular leak syndrome (CLS) (see also under Xr)
X.d X - Systemic conditions, syndromes and reactions
X.d - Lupus - Lupus syndrome (see also Vd)
X.f X - Systemic conditions, syndromes and reactions
X.f - Anaphylaxis
X.g X - Systemic conditions, syndromes and reactions
X.g - Hypersensitivity reaction (may involve skin, throat and/or airways)
X.k X - Systemic conditions, syndromes and reactions
X.k - Sarcoid-like, granulomatous thoracic and/or extrathoracic reaction
X.n X - Systemic conditions, syndromes and reactions
X.n - Tumor lysis syndrome (TLS)
XI.b XI - Miscellaneous
XI.b - Chest pain (acute - subacute)
XI.n XI - Miscellaneous
XI.n - Neutropenia, agranulocytosis (w/wo infection/sepsis)
XI.w XI - Miscellaneous
XI.w - Cavitation/necrosis of lung tumor or metastases
XII.b XII - Cardiovascular involvement / toxicity
XII.b - Valvular heart disease and/or dysfunction
XII.c XII - Cardiovascular involvement / toxicity
XII.c - Pericarditis, pericardial effusion, tamponade
XII.f XII - Cardiovascular involvement / toxicity
XII.f - Cardiomyopathy (acute, subacute, chronic)
XII.g XII - Cardiovascular involvement / toxicity
XII.g - Myocardial ischemia, coronary artery disease, myocardial infarction
XII.l XII - Cardiovascular involvement / toxicity
XII.l - Cardiac arrhythmias or dysrhythmias (AF, VT, VF, TdP)
XII.s XII - Cardiovascular involvement / toxicity
XII.s - Heart block (bundle branch- or AV-)
XII.ai XII - Cardiovascular involvement / toxicity
XII.ai - Cardiotoxicity
XIII.a XIII - Neoplastic conditions
XIII.a - Lung cancer
XIII.b XIII - Neoplastic conditions
XIII.b - Lymphoproliferative disease (pulmonary, endothoracic)
XIII.d XIII - Neoplastic conditions
XIII.d - Malignant mesothelioma (pleural, pericardial)
XV.d XV - Pulmonary pathology
XV.d - Path: Acute fibrinous organizing pneumonia (AFOP-pattern) (see also If)
XV.f XV - Pulmonary pathology
XV.f - Path: Diffuse alveolar damage (DAD-pattern) (see also IL)
XV.i XV - Pulmonary pathology
XV.i - Path: Pneumocyte atypia (reactive epithelial cells)
XV.l XV - Pulmonary pathology
XV.l - Path: Pulmonary fibrosis, unclassifiable
XV.ak XV - Pulmonary pathology
XV.ak - Path: Pulmonary veno-occlusive disease (PVOD)
XV.am XV - Pulmonary pathology
XV.am - Path: Thrombosis in pulmonary arterioles/venules
XV.ba XV - Pulmonary pathology
XV.ba - Path: Granulomatous lymphadenopathy
XVI.ab XVI - Imaging
XVI.ab - Imaging: Cavitating lung nodules (see also Iq, XIs, XIIi, XVIaa and XVIIp)
XVI.af XVI - Imaging
XVI.af - Imaging: Lung cysts or bullae (see also XVI ah/bf)
XVI.bf XVI - Imaging
XVI.bf - Imaging: Tumoral cavitation
XVI.bl XVI - Imaging
XVI.bl - Imaging: Avid lung uptake on PET-scan
XVII.b XVII - Infections & related conditions
XVII.b - Opportunistic pulmonary/systemic infection
XVII.c XVII - Infections & related conditions
XVII.c - Aspergillosis, pulmonary
XVII.e XVII - Infections & related conditions
XVII.e - Pneumocystis jiroveci pneumonia
XVII.g XVII - Infections & related conditions
XVII.g - Tuberculosis (pulmonary, extrapulmonary, reactivation or de novo)
XVII.j XVII - Infections & related conditions
XVII.j - Mucormycosis (pulmonary, tracheobronchial or systemic)
XVII.r XVII - Infections & related conditions
XVII.r - Fungal infection (pulmonary/extrapulmonary)
XVII.af XVII - Infections & related conditions
XVII.af - Reactivation of a prior pulmonary infection (TB, melioidosis)
3

Crack cocaine

I.a I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD), acute, severe (see also under ARDS)
I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD)
I.c I - Interstitial/parenchymal lung disease
I.c - Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)
I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia (A pattern consistent with)
I.e I - Interstitial/parenchymal lung disease
I.e - Acute eosinophilic pneumonia (AEP)
I.g I - Interstitial/parenchymal lung disease
I.g - Pulmonary fibrosis
II.a II - Pulmonary edema - ARDS - Acute respiratory failure
II.a - Pulmonary edema, noncardiogenic (NCPE)
II.b II - Pulmonary edema - ARDS - Acute respiratory failure
II.b - ARDS
II.j II - Pulmonary edema - ARDS - Acute respiratory failure
II.j - Transient pulmonary opacities
III.a III - Pulmonary hemorrhage
III.a - Diffuse alveolar hemorrhage (DAH)
IV.a IV - Airway involvement
IV.a - Bronchospasm - Asthma
IV.c IV - Airway involvement
IV.c - Obliterative bronchiolitis (see also IVn)
IV.e IV - Airway involvement
IV.e - Cough (acute, violent, explosive)
IV.f IV - Airway involvement
IV.f - Severe, catastrophic asthma attack (can be fatal)
V.b V - Pleural and/or pericardial involvement
V.b - Eosinophilic pleural effusion
V.f V - Pleural and/or pericardial involvement
V.f - Pneumothorax
VI.a VI - Pulmonary vasculopathy
VI.a - Pulmonary embolism - Venous thromboembolism
VII.h VII - Mediastinal involvement
VII.h - Pneumomediastinum
VIII.a VIII - Upper, central, large airway involvement
VIII.a - Angioedema (may cause UAO & asphyxia)
VIII.d VIII - Upper, central, large airway involvement
VIII.d - Thermal (burns, frostbite), chemical, or caustic facial and/or airway injury
VIII.m VIII - Upper, central, large airway involvement
VIII.m - Drug foreign body in the airway
VIII.ac VIII - Upper, central, large airway involvement
VIII.ac - Retropharyngeal emphysema
X.ac X - Systemic conditions, syndromes and reactions
X.ac - Anti-GBM antibody disease (Goodpasture-like) or flare of
XI.b XI - Miscellaneous
XI.b - Chest pain (acute - subacute)
XI.c XI - Miscellaneous
XI.c - Pleuritic chest pain (see also under Vi)
XII.g XII - Cardiovascular involvement / toxicity
XII.g - Myocardial ischemia, coronary artery disease, myocardial infarction
XII.l XII - Cardiovascular involvement / toxicity
XII.l - Cardiac arrhythmias or dysrhythmias (AF, VT, VF, TdP)
XII.aa XII - Cardiovascular involvement / toxicity
XII.aa - Arterial (aorta, limb) vasoconstriction and/or ischemia, acute
XII.ae XII - Cardiovascular involvement / toxicity
XII.ae - Aortic dissection
XV.b XV - Pulmonary pathology
XV.b - Path: Eosinophilic pneumonia (subacute or acute) (see also Ic)
XV.e XV - Pulmonary pathology
XV.e - Path: ILD with a granulomatous component (see also Im)
XV.g XV - Pulmonary pathology
XV.g - Path: Alveolar hemorrhage (see also IIIa)
XV.q XV - Pulmonary pathology
XV.q - Path: Foreign body deposits/reaction
XV.s XV - Pulmonary pathology
XV.s - Path: Pneumoconiosis (silicosis, talcosis, talcoma)
XV.bb XV - Pulmonary pathology
XV.bb - Path: Airway inflammation
XV.bj XV - Pulmonary pathology
XV.bj - Path: Alveolar carbonaceous material or deposits
XVI.b XVI - Imaging
XVI.b - Imaging: Ground-glass shadowing/opacities (GGO)
XVI.k XVI - Imaging
XVI.k - Imaging: An area or areas of consolidation
XVIII.l XVIII - Distinctive patterns - 'Eye-catchers'
XVIII.l - Eye catcher: Candy-cane esophagus
1

Cyclophosphamide

I.a I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD), acute, severe (see also under ARDS)
I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD)
I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia (A pattern consistent with)
I.g I - Interstitial/parenchymal lung disease
I.g - Pulmonary fibrosis
I.l I - Interstitial/parenchymal lung disease
I.l - Diffuse alveolar damage (DAD) (see alsoo under IIb and XVf)
I.x I - Interstitial/parenchymal lung disease
I.x - Pleuroparenchymal fibroelastosis (PPFE)
I.aa I - Interstitial/parenchymal lung disease
I.aa - Delayed ILD, -pneumonitis, -fibrosis
II.a II - Pulmonary edema - ARDS - Acute respiratory failure
II.a - Pulmonary edema, noncardiogenic (NCPE)
II.b II - Pulmonary edema - ARDS - Acute respiratory failure
II.b - ARDS
III.a III - Pulmonary hemorrhage
III.a - Diffuse alveolar hemorrhage (DAH)
IV.a IV - Airway involvement
IV.a - Bronchospasm - Asthma
V.a V - Pleural and/or pericardial involvement
V.a - Pleural effusion
V.c V - Pleural and/or pericardial involvement
V.c - Pleural thickening/fibrosis - Fibrothorax
V.f V - Pleural and/or pericardial involvement
V.f - Pneumothorax
VI.c VI - Pulmonary vasculopathy
VI.c - Pulmonary veno-occlusive disease
X.f X - Systemic conditions, syndromes and reactions
X.f - Anaphylaxis
XI.p XI - Miscellaneous
XI.p - Chest deformity: platythorax
XII.a XII - Cardiovascular involvement / toxicity
XII.a - Left ventricular dysfunction/failure
XII.c XII - Cardiovascular involvement / toxicity
XII.c - Pericarditis, pericardial effusion, tamponade
XII.f XII - Cardiovascular involvement / toxicity
XII.f - Cardiomyopathy (acute, subacute, chronic)
XII.g XII - Cardiovascular involvement / toxicity
XII.g - Myocardial ischemia, coronary artery disease, myocardial infarction
XII.s XII - Cardiovascular involvement / toxicity
XII.s - Heart block (bundle branch- or AV-)
XV.a XV - Pulmonary pathology
XV.a - Path: Cellular NSIP pattern (see also Ia, Ib)
XV.h XV - Pulmonary pathology
XV.h - Path: Fibrotic NSIP pattern
XV.i XV - Pulmonary pathology
XV.i - Path: Pneumocyte atypia (reactive epithelial cells)
XV.ak XV - Pulmonary pathology
XV.ak - Path: Pulmonary veno-occlusive disease (PVOD)
XV.ap XV - Pulmonary pathology
XV.ap - Path: Pleuroparenchymal fibrosis/fibroelastosis (PPFE)
XVI.bl XVI - Imaging
XVI.bl - Imaging: Avid lung uptake on PET-scan
XVII.b XVII - Infections & related conditions
XVII.b - Opportunistic pulmonary/systemic infection
XVII.e XVII - Infections & related conditions
XVII.e - Pneumocystis jiroveci pneumonia
XVII.q XVII - Infections & related conditions
XVII.q - Viral pneumonia
XIX.a XIX - Cytology, biochemistry of BAL, pleural fluid or FNA
XIX.a - BAL: An excess proportion of lymphocytes
2

Etanercept

I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD)
I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia (A pattern consistent with)
I.g I - Interstitial/parenchymal lung disease
I.g - Pulmonary fibrosis
I.m I - Interstitial/parenchymal lung disease
I.m - ILD with a granulomatous component
I.q I - Interstitial/parenchymal lung disease
I.q - Nodules in lung parenchyma (a.k.a. nodulosis)
I.w I - Interstitial/parenchymal lung disease
I.w - Rapidly progressive ILD or pulmonary fibrosis (Hamman-Rich syndrome)
I.y I - Interstitial/parenchymal lung disease
I.y - Progression, acceleration or exacerbation of preexisting ILD/fibrosis
III.a III - Pulmonary hemorrhage
III.a - Diffuse alveolar hemorrhage (DAH)
IV.a IV - Airway involvement
IV.a - Bronchospasm - Asthma
V.d V - Pleural and/or pericardial involvement
V.d - Pleural/pericardial effusion, ANA positive (DI lupus)
V.f V - Pleural and/or pericardial involvement
V.f - Pneumothorax
V.m V - Pleural and/or pericardial involvement
V.m - Pleuropericardial effusion (ANA unknown or negative)
VI.a VI - Pulmonary vasculopathy
VI.a - Pulmonary embolism - Venous thromboembolism
VI.d VI - Pulmonary vasculopathy
VI.d - Pulmonary vasculitis or capillaritis
VII.a VII - Mediastinal involvement
VII.a - Lymphadenopathy (intrathoracic)
VIII.a VIII - Upper, central, large airway involvement
VIII.a - Angioedema (may cause UAO & asphyxia)
IX.q IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.q - Obstructive sleep apneas
X.d X - Systemic conditions, syndromes and reactions
X.d - Lupus - Lupus syndrome (see also Vd)
X.e X - Systemic conditions, syndromes and reactions
X.e - Autoimmunity - Autoimmune conditions
X.f X - Systemic conditions, syndromes and reactions
X.f - Anaphylaxis
X.j X - Systemic conditions, syndromes and reactions
X.j - Myositis/polymyositis/DPM/rhabdomyolysis/myopathy
X.k X - Systemic conditions, syndromes and reactions
X.k - Sarcoid-like, granulomatous thoracic and/or extrathoracic reaction
X.m X - Systemic conditions, syndromes and reactions
X.m - Pulmonary and/or systemic vasculitis (ANCA status MPO, unknown or negative)
X.s X - Systemic conditions, syndromes and reactions
X.s - Pulmonary/systemic vasculitis/polyangiitis (ANCA-positive)
X.ar X - Systemic conditions, syndromes and reactions
X.ar - Relapse/flare/onset of Crohn's disease
XI.ad XI - Miscellaneous
XI.ad - Granulomas on tattoo edges
XII.d XII - Cardiovascular involvement / toxicity
XII.d - Myocarditis
XV.a XV - Pulmonary pathology
XV.a - Path: Cellular NSIP pattern (see also Ia, Ib)
XV.c XV - Pulmonary pathology
XV.c - Path: Organizing pneumonia (OP/BOOP) pattern (see also Id)
XV.e XV - Pulmonary pathology
XV.e - Path: ILD with a granulomatous component (see also Im)
XV.ba XV - Pulmonary pathology
XV.ba - Path: Granulomatous lymphadenopathy
XVII.a XVII - Infections & related conditions
XVII.a - Pneumonia - Respiratory tract infection
XVII.b XVII - Infections & related conditions
XVII.b - Opportunistic pulmonary/systemic infection
XVII.f XVII - Infections & related conditions
XVII.f - Tuberculosis, miliary
XVII.g XVII - Infections & related conditions
XVII.g - Tuberculosis (pulmonary, extrapulmonary, reactivation or de novo)
XVII.h XVII - Infections & related conditions
XVII.h - Nontuberculous mycobacterial infection
XVII.ab XVII - Infections & related conditions
XVII.ab - Protozoan infection (incl. leishmaniasis)
2

Excipients - Vehicle - Preservatives

I.c I - Interstitial/parenchymal lung disease
I.c - Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)
I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia (A pattern consistent with)
I.e I - Interstitial/parenchymal lung disease
I.e - Acute eosinophilic pneumonia (AEP)
I.g I - Interstitial/parenchymal lung disease
I.g - Pulmonary fibrosis
I.m I - Interstitial/parenchymal lung disease
I.m - ILD with a granulomatous component
I.t I - Interstitial/parenchymal lung disease
I.t - Pneumoconiosis, talcosis
II.a II - Pulmonary edema - ARDS - Acute respiratory failure
II.a - Pulmonary edema, noncardiogenic (NCPE)
IV.a IV - Airway involvement
IV.a - Bronchospasm - Asthma
IV.f IV - Airway involvement
IV.f - Severe, catastrophic asthma attack (can be fatal)
IV.i IV - Airway involvement
IV.i - Foreign body aspiration bronchiolitis
VI.b VI - Pulmonary vasculopathy
VI.b - Pulmonary arterial hypertension
VI.e VI - Pulmonary vasculopathy
VI.e - Fat/oil embolism
VI.g VI - Pulmonary vasculopathy
VI.g - Foreign body vasculopathy (Excipient lung disease)
X.f X - Systemic conditions, syndromes and reactions
X.f - Anaphylaxis
X.g X - Systemic conditions, syndromes and reactions
X.g - Hypersensitivity reaction (may involve skin, throat and/or airways)
X.u X - Systemic conditions, syndromes and reactions
X.u - Multiple organ dysfunction/failure (MODS/MOF)
XI.d XI - Miscellaneous
XI.d - Metabolic acidosis (incl. lactic-). May cause dyspnea
XII.n XII - Cardiovascular involvement / toxicity
XII.n - Hypotension, shock, cardiovascular collapse
XV.q XV - Pulmonary pathology
XV.q - Path: Foreign body deposits/reaction
XV.ae XV - Pulmonary pathology
XV.ae - Path: Lipid/fat embolism (see also VIe)
XVI.q XVI - Imaging
XVI.q - Imaging: A pattern similar/consistent to/with IPF
XVI.v XVI - Imaging
XVI.v - Imaging: Diffuse centrilobular micronodules
1